PreciseBreast®
Early-stage, HR+, HER2- Breast Cancer Risk Stratification
Key Facts
About PreciseDx
PreciseDx is a private, commercial-stage diagnostics company using artificial intelligence to transform cancer prognosis. Its core technology, the OncoIntelligence platform, analyzes digitized pathology slides to deliver a quantitative risk score for breast cancer recurrence in hours, addressing a critical bottleneck in current care pathways. The company targets the significant market of intermediate-grade breast cancer patients, offering a faster, more objective, and cost-effective alternative to traditional gene expression profiling. Founded in 2017 by renowned pathologist Dr. Carlos Cordon-Cardo, PreciseDx is positioned to improve clinical decision-making and patient anxiety by accelerating diagnostic clarity.
View full company profile